Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irdabisant
- Development stage
- Phase 1
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Irdabisant is a selective, orally active small molecule that acts as an inverse agonist and antagonist of the histamine H3 receptor. It was developed for its potential to enhance cognition and promote wakefulness by modulating neurotransmitter release in the brain, particularly dopamine and norepinephrine. Irdabisant has demonstrated high affinity for human (Ki = 2.0 nM) and rat (Ki = 7.2 nM) H3 receptors with over 1000-fold selectivity against other histamine receptor subtypes and a broad panel of other targets. The drug was investigated primarily for cognitive impairment associated with schizophrenia but did not progress beyond early clinical development[1][2][3][4][5][6][7].
- Other names
- irdabisantum1005402-19-6WH7ISP34KAWH-7ISP34KAWH 7ISP34KA
02
Targets
ADRA1A (α1A)DAT (Dopamine plasma membrane transport protein)HRH3 (Histamine Receptor H3)CHRM2 (M2)NET (Norepinephrine Transporter)PDE3KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on Irdabisant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irdabisant.